The Fetal Safety of Statins: A Systematic Review and Meta-Analysis

Zarek, Judith; Koren, Gideon

doi:10.1016/s1701-2163(15)30565-x

Cited by 69 publications

(56 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…55 Simvastatin's and rosuvastatin's safety in pregnancy is a valid concern for physicians because the FDA labels statins as a Category X drug. 56,57 However, it is essential to understand that this categorization was based on limited animal data on lovastatin only, and it was then generalized to newer generations of statins, which have different pharmacological properties. Potential teratogenicity of statins reported include impairment in gonadal steroidogenesis due to inhibition of cholesterol synthesis; however, no conclusive evidence has shown that.…”

Section: Discussionmentioning

confidence: 99%

Regulation of p38 mitogen‐activated kinase‐mediated fetal membrane senescence by statins

Ayad

Taylor

Menon

2018

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Regulation of p38 mitogen‐activated kinase‐mediated fetal membrane senescence by statins

Ayad

Taylor

Menon

2018

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

“…Similar effects have been shown in human fetal membranes 142 . Several large prospective studies are underway to confirm reports 143, 144 that statin administration is safe in pregnancy.…”

Section: Recent Advancesmentioning

confidence: 93%

Recent advances in the prevention of preterm birth

Keelan

Newnham

2017

F1000Res

View full text Add to dashboard Cite

Preterm birth (PTB) remains a major obstetric healthcare problem and a significant contributor to perinatal morbidity, mortality, and long-term disability. Over the past few decades, the perinatal outcomes of preterm neonates have improved markedly through research and advances in neonatal care, whereas rates of spontaneous PTB have essentially remained static. However, research into causal pathways and new diagnostic and treatment modalities is now bearing fruit and translational initiatives are beginning to impact upon PTB rates. Successful PTB prevention requires a multifaceted approach, combining public health and educational programs, lifestyle modification, access to/optimisation of obstetric healthcare, effective prediction and diagnostic modalities, and the application of effective, targeted interventions. Progress has been made in some of these areas, although there remain areas of controversy and uncertainty. Attention is now being directed to areas where greater gains can be achieved. In this mini-review, we will briefly and selectively review a range of PTB prevention strategies and initiatives where progress has been made and where exciting opportunities await exploitation, evaluation, and implementation.

show abstract

“…(36, 38–45) This could be expected due to pravastatin’s unique pharmacokinetic properties. Pravastatin is one of the most hydrophilic and hepatoselective statins with a short half-life, which will limit its transplacental transfer.…”

Section: Teratogenicity Concerns For Using Pravastatin In Pregnancymentioning

confidence: 99%

Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?

Marrs

Costantine²

2017

Clinical Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Preeclampsia is a multisystem disorder that affects 3–5% of pregnant women and remains a significant source of short- and long-term maternal and neonatal mortality and morbidity. Many professional societies recommend the use of low dose aspirin to prevent preeclampsia in high-risk women. Due to the similarities in pathophysiology between preeclampsia and atherosclerotic cardiovascular disease, and the encouraging data from preclinical and pilot clinical studies, pravastatin has been proposed for preventing preeclampsia. However, before statin administration becomes part of routine clinical practice, a large, well-designed, and adequately powered randomized controlled trial is needed.

show abstract

The Fetal Safety of Statins: A Systematic Review and Meta-Analysis

Cited by 69 publications

References 21 publications

Regulation of p38 mitogen‐activated kinase‐mediated fetal membrane senescence by statins

Regulation of p38 mitogen‐activated kinase‐mediated fetal membrane senescence by statins

Recent advances in the prevention of preterm birth

Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?

Contact Info

Product

Resources

About